On the Economic Infeasibility of Personalized Medicine, and a Solution.

Veronesi acknowledges financial support from the Fama-Miller Center for Research in Finance and by the Center for Research in Security Prices at the University of Chicago Booth School of Business. For useful comments, we thank workshop participants at the Chicago Fed, Bocconi University, and University of Chicago. We also thank Salem Soin-Voshel for excellent research assistance. Errors are our own. The views expressed in this paper are our own and do not necessarily reflect the views of our respective employers. Siniscalchi declares that he has no relevant or material financial interests that relates to the research described in this paper. Garassino, and Veronesi’s partner, declares that she serves as paid consultant of several pharmaceutical companies, and also serves on their steering committees for clinical trials. Odunsi is supported by P30CA014599 grant from the NIH and is a co-founder of Tactiva Therapeutics. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.